Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients by Garcia, Riberto et al.
457
Braz J Med Biol Res 40(4) 2007
CNI-free regimens in living kidney transplant recipients
www.bjournal.com.br
Brazilian Journal of Medical and Biological Research (2007) 40: 457-465
ISSN 0100-879X
Exploratory calcineurin inhibitor-free
regimens in living-related kidney
transplant recipients
1Divisão de Nefrologia, Hospital do Rim e Hipertensão,
Universidade Federal de São Paulo, São Paulo, SP, Brasil
2Departamento de Patologia, Universidade Federal de São Paulo,
São Paulo, SP, Brasil
R. Garcia1, P.G. Machado1,
C.R. Felipe1, S.I. Park1,
G.A. Spinelli1, M.F. Franco2,
H. Tedesco-Silva Jr.1
and J.O. Medina-Pestana1
Abstract
Chronic allograft nephropathy is among the major causes of graft loss
even in low-risk kidney transplant recipients and correlates with acute
nephrotoxic events during the first year post-transplant. Therefore,
calcineurin inhibitor-free regimens may improve patient and graft
survival among recipients of living-related kidney transplants. To
confirm this hypothesis, we evaluated the efficacy and safety of two
calcineurin inhibitor-free regimens in 92 low-risk recipients of one-
haplotype living-related kidney transplants. Immunosuppression con-
sisted of tacrolimus, azathioprine and prednisone (group I, GI, N =
38), 2 doses of daclizumab, mycophenolate mofetil (MMF), and
prednisone (GII, N = 33) and 2 doses of daclizumab, MMF, sirolimus
and prednisone (GIII, N = 21). At 12 months, treatment failure
(biopsy-confirmed acute rejection, graft loss or death) was higher in
GII compared to GIII and GI (54.5 vs 24.0 vs 13.1%, P < 0.01,
respectively). In patients of black ethnicity the incidence of acute
rejection was 25 vs 83.3 vs 20% (P = 0.055), respectively. Patient and
graft survival was comparable. There were no differences in mean
creatinine or calculated creatinine clearance at 12 months. Overall
incidence of post-transplant diabetes mellitus (3.3%) and cytomega-
lovirus disease (4.3%) was similar in all groups. Further development
of effective calcineurin inhibitor-free regimens should exclude pa-
tients of black ethnicity and may need full-induction therapy, perhaps
with depleting agents, and concentration-controlled use of sirolimus
and MMF.
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Introduction
Recipients of living kidney allografts con-
sistently demonstrate superior graft survival
compared to recipients of deceased donors
(1). Younger and healthy donors, better HLA
matching, less ischemia/reperfusion injury
and shorter time on dialysis may account for
these findings (1,2). Nevertheless, even
among living donor kidney transplant recipi-
ents, major causes of graft loss are chronic
allograft nephropathy and death with a func-
tioning graft (1). Chronic allograft nephrop-
athy correlates with the occurrence of acute
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nephrotoxic events during the first year post-
transplant. In addition, since renal function
is closely related to long-term kidney graft
survival (3) and is a strong risk factor for
cardiovascular death (4), the search for ef-
fective immunosuppressive regimens that
do not rely on calcineurin inhibitors may
result in improvement of long-term outcome,
minimizing the systemic and allograft toxic-
ity and maintaining the current low-acute
rejection rates (5).
Avoidance and early withdrawal of cal-
cineurin inhibitors under different induction
protocols and adjuvant regimens are cur-
rently being tested for efficacy and safety in
a variety of kidney transplant populations
with different risk factors. One of the first
attempts was described by Vincenti et al. (5)
using induction with a 5-dose course of
daclizumab and mycophenolate mofetil
(MMF) at doses of 3 g/day for at least 6
months. This group presented an unaccept-
ably high incidence of acute rejection but
excellent graft function within the first year.
However, only 14% of the recipients re-
ceived grafts from living-related donors.
Later, cyclosporine withdrawal after three
months with maintenance of the sirolimus
(SRL) and prednisone combination presented
a low incidence of acute rejection and better
graft function at one year when compared
with patients maintained on low-dose cyclo-
sporine, SRL and prednisone (6,7). Similar
results were observed with cyclosporine with-
drawal after 3 months in patients receiving
MMF and prednisone (8,9). In all of these
studies a slightly higher incidence of acute
rejection was observed after cyclosporine
withdrawal. More recently, a calcineurin in-
hibitor-free regimen consisting of basilix-
imab induction followed by a combination
of SRL, MMF and prednisone showed a less
than 10% acute rejection rate and excellent
one-year graft function (10). In that study,
about 25% of the recipients received allo-
grafts from living-related donors.
Although the efficacy of calcineurin in-
hibitor-free regimens still needs to be con-
firmed in higher risk populations, especially
those without effective induction with poly-
clonal antibodies, on the basis of the studies
conducted thus far, it appears that these regi-
mens may be effective in a low-risk trans-
plant population. We report here our initial
experience with two calcineurin inhibitor-
free regimens in a selected low-risk kidney
transplant population.
Subjects and Methods
Subjects
Between January 6, 2001 and August 16,
2003, 92 recipients of first one-haplotype
living-related kidney transplants were eli-
gible for inclusion in this prospective single
center study. Women of childbearing age
were required to have a negative pregnancy
test before administration of the medications
under study and to practice medically ap-
proved birth control throughout the study
and for 3 months after discontinuation of
SRL. The protocol also required the patients
to have a total white blood cell count >4.0 x
109/L, platelet count >100.0 x 109/L, fasting
cholesterol <350 mg/dL (<9.1 mmol/L), and/
or fasting triglycerides <500 mg/dL (<5.65
mmol/L) during a pre-transplant screening
evaluation. Patients were excluded if they
had evidence of systemic infection or a his-
tory of clinically significant cardiac abnor-
malities or malignancy within 10 years. All
patients were required to have had a nega-
tive T cell crossmatch. The local Ethics Com-
mittee approved the protocol and all patients
were required to sign an informed consent
form.
Trial design
We included in this trial only recipients
of one-haplotype living-related allografts in
order to obtain a more homogeneous popu-
lation during the analysis of the primary
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end-points due to the relatively small num-
ber of patients allocated to each study group.
Patients were enrolled and randomized be-
fore transplantation. During an initial phase
patients were randomized to receive tacroli-
mus, azathioprine and prednisone (group I,
GI), or two-doses dacluzimab induction (11)
followed by a combination of MMF and
prednisone (GII). Since an interim analysis
revealed an excessive acute rejection rate
among patients in GII, enrollment was inter-
rupted on July 25, 2002 and a third group of
patients was enrolled in a non-randomized
fashion between January 23 and August 16,
2003 according to the same inclusion and
exclusion criteria and treated with two-dose
dacluzimab induction followed by a combi-
nation of MMF, SRL and prednisone (GIII).
Immunosuppressive therapy
GI patients received tacrolimus, 0.1 mg/
kg, twice daily, administered within 24 h of
graft revascularization. Tacrolimus doses
were then adjusted to maintain trough blood
concentrations between 10 and 20 ng/mL
during the first month, between 8 and 15 ng/
mL during the second month, and between 5
and 8 ng/mL thereafter, measured by IMX
System immunoassay using a specific mono-
clonal antibody against tacrolimus (IMX
System, Abbott Diagnostics, Abbott Park,
IL, USA). Patients also received fixed daily
azathioprine doses of 2 mg/kg. GII patients
received two doses of 1 mg/kg daclizumab,
one before graft revascularization and the
other on day 14. MMF, 3 g/day, was initiated
within 24 h and reduced to 2 g/day at 30
days. GIII patients received the same
daclizumab treatment as GII, 2 g/day MMF
and a 6-mg loading dose followed by 2 mg
fixed daily doses of SRL, all initiated within
24 h. Whole blood SRL concentrations were
measured by HPLC (12) after 7 and 14 days,
and after 1, 2, 3, 6, 9, and 12 months. All
patients received 1 g methylprednisolone
before graft revascularization, followed by
daily prednisone doses of 0.5 mg kg-1 day-1
(maximum of 30 mg/day) for 30 days. Pred-
nisone was tapered to 20 mg/day by month
2, reaching 10 mg/day between months 3
and 6. No further reductions or steroid with-
drawal were permitted by the protocol. All
drugs were adjusted for safety and tolerabil-
ity based on clinical findings.
Prophylaxis for Pneumocystis carinii
pneumonia with trimethoprim-sulfamethox-
azole was mandatory for all patients during
the 12-month treatment period. None of the
patients received prophylaxis for cytomega-
lovirus infection.
Unless contraindicated, patients with
clinical and/or laboratory findings sugges-
tive of acute rejection were required to un-
dergo a graft biopsy to confirm the clinical
diagnosis. A local pathologist graded the
histological diagnoses according to the 1997
Banff criteria. Initial therapy for acute rejec-
tion consisted of a 3- to 5-day course of at
least 500 mg methylprednisolone daily. Pa-
tients who failed to respond to steroid thera-
py were treated with polyclonal antibodies.
Delayed graft function was defined as a need
for dialysis during the first post-transplant
week. Graft loss was defined as physical loss
due to nephrectomy, functional loss requir-
ing maintenance dialysis for more than 8
weeks, or death with a functioning graft.
Endpoints
The primary efficacy endpoint was the
rate of efficacy failure during the first 12
months after transplantation. Efficacy fail-
ure was defined as the first occurrence of a
biopsy-confirmed acute rejection, graft loss
or death. Secondary efficacy endpoints were:
1) the incidence, time and histological grade
of first biopsy-confirmed acute rejection; 2)
the incidence of all treated rejections, anti-
body-treated rejections and repeated rejec-
tions; 3) patient, graft and functioning (death-
censored) graft survival.
Safety analysis included hematology,
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ables. To test the pre-transplantation equiva-
lence of the two groups, the Student t-test
was used for age, weight, height, vital signs,
and laboratory determinations. The chi-
square test was used to compare the distribu-
tion of nominal attributes such as sex, ethnic
origin and medical history. The primary effi-
cacy endpoints (rates of first biopsy-con-
firmed acute rejection episode, graft loss
and death) were analyzed using the chi-
square test. Hematologic and biochemical
data were evaluated by analysis of covari-
ance, with group as factor and the measure-
ment at first visit after transplantation as
covariate. The time to the first biopsy-con-
firmed acute rejection episode and the histo-
logical grade of the first acute rejection were
evaluated by analysis of variance. Incidences
biochemistry, lipid profile, and graft function
measured by serum creatinine and calculated
creatinine clearance (13). The occurrence of
lymphoproliferative disease or other malig-
nancies, serious adverse events, infections,
and the frequency and reason for discontinua-
tion of the drugs under study were also ana-
lyzed.
Statistical analysis
All patients in all groups were evaluated
for the primary efficacy endpoints in an
intention-to-treat analysis during the first 12
months after transplantation. Per protocol
population was defined as the population
completing 12 on randomized therapy. De-
scriptive statistics was provided for all vari-
Table 1. Demographic characteristics of the transplant patients before and after the 12-month study.
Total (N = 92) GI (N = 38) GII (N = 33) GIII (N = 21)
Age (years) 36.0 ± 11.1 37.4 ± 11.6 33.0 ± 10.0 38.2 ± 11.0
Body mass index (kg/m2) 23.4 ± 4.1 23.7 ± 4.3 22.7 ± 3.5 24.0 ± 4.9
Gender
Male 55 (60%) 21 (55%) 22 (67%) 12 (57%)
Female 37 (40%) 17 (45%) 11 (33%) 9 (43%)
Ethnicity
White 76 (83%) 34 (89%) 27 (82%) 15 (71%)
Black 15 (16%) 4 (11%) 6 (18%) 5 (24%)
Other 1 (1%) 0 (0%) 0 (0%) 1 (5%)
Cause of end-stage renal disease
Hypertension 31 (33%) 12 (31%) 15 (45%) 4 (19%)
Chronic glomerulonephritis 22 (24%) 12 (31%) 7 (21%) 3 (14%)
Diabetes mellitus 2 (2%) 0 (0%) 2 (7%) 0 (0%)
Others 37 (41%) 14 (38%) 9 (27%) 14 (67%)
Time on dialysis (months) 20.1 ± 19.0 16.7 ± 10.8 20.0 ± 19.3 26.5 ± 27.0
Panel reactive antibody >5% 7 (8%) 2 (5%) 2 (6%) 3 (14%)
Donor age (years) 48.0 ± 11.1 48.3 ± 10.8 46.3 ± 10.8 50.0 ± 12.5
Delayed graft function 1 (5%) 0 (0%) 0 (0%) 1 (5%)
Patients per-protocol at 12 months* 67 (73%) 33 (87%) 16 (48%) 18 (86%)
Graft loss 2 (2%) 1 (2.6%) 0 (0%) 0 (0%)
Death 3 (3.3%) 1 (2.6%) 2 (6.0%) 0 (0%)
Withdrawn due to adverse events 3 (0.3%) 0 (0%) 0 (0%) 3 (14%)
Withdrawn due to lack of efficacy* 19 (21%) 3 (8%) 16 (48%) 0 (0%)
Data are reported as means ± SD or as number of patients with percent in parentheses. GI = group I patients
immunosuppressed with tacrolimus, azathioprine, prednisone; group II (GII) = daclizumab (2 doses), myco-
phenolate mofetil, prednisone; group III (GIII) = daclizumab (2 doses), mycophenolate mofetil, sirolimus,
prednisone.
*P < 0.05 for GI vs GII vs GIII (ANOVA).
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of treated rejection episodes (with or with-
out biopsy confirmation), adverse events,
infections, lymphoproliferative disease, and
malignancy were compared by the Fisher
exact test. Blood levels of tacrolimus and
sirolimus are reported as means ± SD. Patient
and graft survival were calculated using
Kaplan-Meier estimates and differences among
groups were determined by the log-rank test.
All statistical tests were two-sided at the
5% level of significance. The 95% confi-
dence intervals were calculated when pos-
sible. Data are reported as means ± SD un-
less otherwise indicated.
Results
Demographics and baseline characteristics
The demographic characteristics of the
allograft recipients were similar across treat-
ment groups (Table 1). Overall this was a
low-risk transplant population consisting pre-
dominantly of young, non-obese, white male
recipients. Most of them were non-sensi-
tized but mean time on dialysis was rela-
tively long (20.1 ± 19.0 months). Only 1
patient in GIII developed delayed graft func-
tion. At 12 months the proportion of patients
receiving randomized therapy (per protocol
population) was higher in GI and GIII com-
pared to GII (87 vs 86 vs 48%, P < 0.01,
Table 1).
Immunosuppression
Mean doses and concentrations are shown
in Table 2. In GI mean tacrolimus concentra-
tions in whole blood were 14.6 ± 5.0, 9.2 ±
2.7, 7.6 ± 3.2, and 7.0 ± 2.4 ng/mL at 1, 3, 6,
and 12 months, respectively. Mean azathio-
prine doses were 129.0 ± 26.7 and 129.5 ±
22.7 mg/day at 1 and 12 months, respective-
ly. In GII mean MMF doses were 2.8 ± 0.4,
2.2 ± 0.4 and 1.8 ± 0.5 g/day at 14 and 30
days and at 12 months, respectively. In GIII
mean trough SRL concentrations in whole
blood were 7.4 ± 4.4, 6.4 ± 4.0, 6.0 ± 3.5, and
7.2 ± 3.6 ng/mL at 1, 3, 6, and 12 months,
and mean MMF doses were 2.0 ± 0.0, 2.0 ±
0.0 and 1.9 ± 0.5 g/day at 14 and 30 days and
at 12 months, respectively. Faster steroid
taper was observed among GI patients be-
tween months 2 and 9 but no differences
were observed at 1 year, with overall mean
values of 9.7 ± 4.2 mg/day.
Table 2. Doses and blood concentrations of immunosuppressive drugs during the first 12 months after
transplantation.
Day GI (N = 38) GII (N = 33) GIII (N = 21)
TAC Blood TAC PRED MMF PRED Blood SRL MMF PRED
dose concentration  dose dose dose concentration dose dose
(mg/day) (ng/mL) (mg/day) (g/day) (mg/day) (ng/mL) (g/day) (mg/day)
7 18.6±9.7 20.4±6.2 28.6±4.2 3.0±0.2 28.8±2.9 5.4±2.0 2.0±0.0 28.7±2.7
14 18.6±6.1 19.2±6.5 28.0±4.0 2.8±0.4 28.5±3.2 8.0±11.3 2.0±0.0 29.0±2.7
30 13.3±6.3 14.6±5.0 25.1±7.3 2.2±0.4 27.8±3.8 7.4±4.4 2.0±0.0 28.1±3.7
60 10.7±5.5 12.0±4.6 17.8±5.0* 2.1±0.4 24.3±8.0 7.5±4.3 2.0±0.2 20.4±3.5
90 8.4±4.7 9.2±2.7 14.0±6.2* 2.0±0.5 20.0±6.6 6.4±4.0 2.0±0.2 14.8±6.0
180 6.6±4.2 7.6±3.2 8.2±2.5* 2.0±0.5 11.1±3.1 6.0±3.5 2.0±0.3 10.1±1.2
270 6.5±3.8 7.4±2.0 8.5±3.2* 2.0±0.5 10.3±2.3 7.6±4.4 1.9±0.4 10.2±1.1
360 5.9±3.1 7.0±2.4 9.5±6.6 1.8±0.5 9.8±1.6 7.2±3.6 1.9±0.5 9.9±0.5
Data are reported as means ± SD. TAC = tacrolimus; PRED = prednisone; MMF = mycophenolate mofetil;
SRL = sirolimus. For group definitions, see legend to Table 1.
*P < 0.01 for GI vs GII vs GIII (ANOVA).
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all groups (P < 0.01, Table 3). GI patients
showed a lower rate of acute rejection com-
pared to GII or GIII patients (10.5 vs 48.5 vs
24.0%, P < 0.01). Addition of SRL reduced
the incidence of acute rejection in GIII com-
pared to GII (24.0 vs 48.5%, P < 0.05).
Similar findings were observed when com-
paring the incidence of all treated rejections
(15.8 vs 48.5 vs 38.1%, P < 0.01). In patients
of black ethnicity, the incidence of acute
rejection was higher in GII compared to GI
and GIII (83.3 vs 25 vs 20%, P = 0.055).
Mean time to first biopsy-confirmed acute
rejection was shorter in GI patients com-
pared to GII and GIII (21.7 vs 59.1 vs 37
days, P = 0.092). No significant differences
were observed in the severity of first biopsy-
confirmed acute rejection, according to the
BANFF criteria (P = 0.476) or of repeat
rejections (2.6 vs 9.0 vs 4.7%, P = 0.482) and
severe or steroid-resistant rejection that re-
quired treatment with antibodies (5.2 vs 6.1
vs 0.0%, P = 0.532). Only one graft loss (GI)
and 3 deaths (1 in GI and 2 in GII) were
observed. Patient survival was comparable
(97.4 vs 94.0 vs 100%, ns) as also was graft
survival (94.8 vs 94.0 vs 100%, ns) and
functioning graft survival (97.4 vs 100 vs
100%, ns). Compared to GI and GIII, more
patients in GII were switched to an alterna-
tive immunosuppressive regimen due to lack
of efficacy (8 vs 48 vs 0%, P < 0.01, Table 1).
Safety
Hematology, biochemistry, and lipid pro-
files. At 12 months, mean hemoglobin and
white blood cell and platelet counts were
within the normal range, with no significant
differences among groups. No significant
differences were observed in mean glucose
concentrations or hepatic function tests.
Mean triglyceride and cholesterol concen-
trations were higher in GIII on day 14 and
during month 1, respectively, and these dif-
ferences were maintained up to 12 months
after transplantation (Table 4).
Table 3. Primary and secondary efficacy end-points at 12 months.
GI (N = 38) GII (N = 33)  GIII (N = 21)
Composite primary end-point* 5 (13.1%) 18 (54.5%) 5 (24.0%)
BCAR* 4 (10.5%) 16 (48.5%) 5 (24.0%)
Time to first BCAR (days) 21.7 ± 16.2 59.1 ± 42.0 37.0 ± 34.5
Severity of BCAR (N)
IA 1 6 4
IB 0 2 1
IIA 2 5 0
IIB 0 2 0
III 1 1 0
Treated rejections* 6 (15.8%) 16 (48.5%) 8 (38.1%)
Second rejection 1 (2.6%) 3 (9.0%) 1 (4.7%)
Antibody-treated rejection 2 (5.2%) 2 (6.1%) 0 (0%)
1-year patient survival  (97.4%)  (94.0%)  (100%)
1-year graft survival  (94.8%)  (94.0%)  (100%)
1-year functioning graft survival  (97.4%)  (100%)  (100%)
Data are reported as number of patients with percent in parentheses and means ± SD.
BCAR = biopsy-confirmed acute rejection according to BANFF criteria. For group
definitions, see legend to Table 1.
*P < 0.05 for GI vs GII vs GIII (ANOVA).
Table 4. Hematology, blood chemistry and renal function at 12 months.
Parameters GI (N = 38) GII (N = 33)  GIII (N = 21)
Hemoglobin (g/dL) 13.7 ± 2.0 13.3 ± 2.4 12.8 ± 1.8
Hematocrit (%) 41.2 ± 6.0 41.6 ± 7.7 39.8 ± 5.4
White blood cells (N/mm3) 8647 ± 3678 7780 ± 2218 7409 ± 2734
Platelets (103/mm3) 206.2 ± 44.8 232.7 ± 62.5 228.0 ± 61.2
Cholesterol (mg/dL) 194 ± 42 197 ± 34 251 ± 51*
Triglycerides (mg/dL) 165 ± 97 154.0 ± 73 289.0 ± 151*
Glucose (mg/dL) 83 ± 13 89 ± 33 81 ± 11
Creatinine (mg/dL) 1.6 ± 0.7 1.7 ± 0.8 1.6 ± 0.8
Creatinine clearance (mL/min) 58.9 ± 14.0 56.9 ± 16.4 59.3 ± 21.4
Data are reported as means ± SD. For group definitions, see legend to Table 1.
*P < 0.01 for GIII compared to other groups (ANOVA).
Efficacy
Primary efficacy end-point. At 12 months
treatment failure was significantly higher in
GII compared to GIII and GI (54.5 vs 24.0 vs
13.1%, P < 0.01, Table 3), respectively.
There was no significant difference between
GI and GIII (P = 0.174).
Secondary efficacy end-points. There was
a significant difference in the incidence of
first biopsy-confirmed acute rejection among
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Graft function. Overall, in the intention-
to-treat population there were no differences
in mean creatinine or calculated creatinine
clearance at 12 months (Table 4). GIII pa-
tients who developed acute rejection showed
worst graft function compared to patients
without acute rejection (2.4 ± 1.3 vs 1.3 ± 0.3
mg/dL, P < 0.01, Table 5). At 12 months a
higher proportion of GI patients showed
creatinine values less than 1.5 mg/dL com-
pared to GII and GIII (75 vs 58 vs 57%, P =
0.399). On the other hand, a high proportion
of patients in all groups showed a delta
creatinine of less than 0.5 mg/dL between
months 6 and 12 (92 vs 94 vs 90%, P =
0.462). Similar results were observed in the
per-protocol population (Table 5).
Adverse events, infections and malignan-
cies. Post-transplant diabetes mellitus was
observed in 3 (3.3%) patients, with no sig-
nificant differences among groups (2.6 vs
6.1 vs 0.0%, ns). Tolerability of MMF and/
or SRL was very good, as demonstrated by
few dose changes and by the mean doses
administered at 12 months. Overall inci-
dence of cytomegalovirus infection was 4
(4.3%), with no significant differences among
groups (2.6 vs 0.0 vs 14.3%, ns).
Discussion
One-haplotype living-related kidney trans-
plants account for 28% of our annual trans-
plant activity. Our attempt to develop a cal-
cineurin inhibitor-free immunosuppressive
regimen for a low-risk transplant population
did not meet our main expectations, i.e.,
reducing allograft toxicity and keeping the
current low-acute rejection rate. The control
group, which received tacrolimus, azathio-
prine, prednisone, and no induction therapy
showed a lower incidence of rejections, simi-
lar one-year renal function and patient and
graft survival and very good tolerability and
safety profile compared to MMF (GII) or to
the MMF/SRL (GIII) combination. Appar-
ently this control group did even better than
similar populations in which acute rejection
rates are about 30%. Careful analysis of
these results allowed us to identify possible
Table 5. Analysis of graft function at 12 months according to the occurrence of acute rejection in the intention-
to-treat and per-protocol population.
Intention-to-treat GI (N = 36) GII (N = 31) GIII (N = 21)
Acute rejection Yes (N = 3) No (N = 33) Yes (N = 15) No (N = 16) Yes (N = 5) No (N = 16)
Mean creatinine 1.6 ± 0.5 1.6 ± 0.7 1.9 ± 0.7 1.5 ± 0.8 2.4 ± 1.3 1.3 ± 0.3*
(mg/dL)
Patients with 25% 75% 42% 58% 43% 57%
Cr >1.5 mg/dL
Patients with   8% 92% 6% 94% 10% 90%
∆Cr >0.5 mg/dL
Per-protocol GI (N = 33) GII (N = 16) GIII (N = 18)
Acute rejection Yes (N = 2) No (N = 31) Yes (N = 0) No (N = 16) Yes (N = 2) No (N = 16)
Mean creatinine 1.6 ± 0.8 1.6 ± 0.7 - 1.5 ± 0.8 1.6 ± 0.3 1.3 ± 0.3
(mg/dL)
Patients with 24% 76% 31% 69% 33% 67%
Cr >1.5 mg/dL
Patients with 9% 91% 6% 94% - 100%
∆Cr >0.5 mg/dL
Data are reported as means ± SD or as percent. ∆Cr >0.5 mg/dL = comparing values at 6 and 12 months (Ref.
3). For group definitions, see legend to Table 1.
*P < 0.01 comparing mean creatinine values of patients with or without acute rejection in GIII (ANOVA).
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reasons, namely: 1) inappropriate induction
therapy in both GII and GIII, 2) a premature
reduction of the MMF dose in GII, 3) insuf-
ficient SRL exposure in GIII, 4) lack of
prospective serum mycophenolic acid (MPA)
measurement in the absence of a calcineurin
inhibitor, and 5) ethnicity.
Perhaps full 5-dose courses of daclizumab
would be ideal in a calcineurin-inhibitor free
regimen even in this low-risk transplant popu-
lation. Two 1-mg/kg doses of daclizumab
produce IL-2 receptor saturation for about
10 weeks (11). In GII and GIII, 30 and 29%
of rejections occurred after week 8, respec-
tively. However, in a similar study in which
Vincenti et al. (14) employed a regimen with
five doses of daclizumab, the biopsy-proven
acute rejection was diagnosed in 21% at day
30 and 38% at day 90.
Another shorter alternative strategy in-
cludes 2 doses of 2 mg/kg daclizumab, which
produce effective antibody concentrations
and prolonged saturation of IL-2Rα on cir-
culating lymphocytes (14).
Early reduction in MMF doses at 15 days
may also have contributed, at least in part, to
the higher incidence of acute rejection, par-
ticularly in GII, taking into account the ex-
cellent tolerability observed in the absence
of a calcineurin inhibitor. Vincenti et al. (5)
employed doses of 3 g for at least 6 months.
In the present study, the addition of a 2-mg
fixed dose of SRL, which resulted in mean
trough concentrations of 6-8 ng/mL, reduced
the incidence of acute rejection from 48.5 to
24% (P = 0.07). Still, this rate of acute
rejection is higher than the 6.4% observed
by Flechner et al. (10) in a low-risk popula-
tion. In that trial, Flechner et al. used induc-
tion with basiliximab (two doses of 20 mg on
days 0 and 4) and targeted SRL trough con-
centrations to 10-12 ng/mL. Contrasting with
the excellent MMF tolerability observed in
the present study (Table 2), about one third
of the patients in the cited study (10) did not
tolerate 2 g of MMF and mean serum MPA
trough concentrations were around 5 mg/L,
indicating that higher SRL trough concen-
trations may be involved in both efficacy
and toxicity (10). There is a growing body of
data suggesting that MPA serum therapeutic
drug monitoring may be useful especially in
the absence or reduced doses of calcineurin
inhibitor (15). Unfortunately, target thera-
peutic concentrations under these circum-
stances have not been identified or tested
prospectively in large trials. Finally, patients
of black ethnicity have been considered to
be at high immunological risk to develop
acute rejection and inferior graft survival.
The higher incidence of rejection observed
in patients of black ethnicity in GII suggests
that a better HLA matching offered by liv-
ing-related one-haplotype kidney allografts
does not reduce substantially the risk for
acute rejection. These patients may still need
a calcineurin inhibitor-based immunosup-
pressive regimen to present low rates of
acute rejection (16).
The higher and later occurrence of acute
rejection episodes mitigated the benefit of
the calcineurin inhibitor-free regimens (GII
and GIII) for graft function. At 1 year, mean
creatinine values did not differ among groups.
Moreover, in GII and GIII, patients with
acute rejection showed higher mean creati-
nine levels than those without acute rejec-
tion. The percentage of patients with good
renal function at 1 year (creatinine values
less than 1.5 mg/dL) was similar for the
three groups in the per-protocol population
but higher in the tacrolimus group in the
intention-to-treat population. In addition,
despite the higher incidence of acute rejec-
tion in GI and GII, the incidence of anti-
body-treated rejection and repeated rejec-
tion was similar in all three groups, suggest-
ing that the rejections which lead to a change
in the immunosuppressive therapy resulted
in sustained impaired graft function, inde-
pendently of the histological grades and of
resistance or not to steroid treatment. The
lack of a 1-year biopsy, however, precludes
more conclusive analysis. Interestingly, sta-
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bility of graft function between months 6
and 12 was observed in a high proportion of
patients (intention-to-treat or per-protocol)
in all three groups.
The safety profile of all three regimens
was benign, with low incidences of post-
transplant diabetes mellitus and cytomega-
lovirus disease, although a typical increase
in cholesterol and triglyceride concentra-
tions was observed in GIII patients.
Further development of an effective cal-
cineurin inhibitor-free regimen for one-hap-
lotype living-related kidney transplant re-
cipients should exclude patients of black
ethnicity and may need full-induction thera-
py, perhaps with depleting agents, and use of
SRL and MMF at controlled concentrations.
In summary, the combination of tacrolimus,
azathioprine and prednisone appears to be
ideal for these low-risk kidney transplant
patients. Alternative schedules allowing
minimization or elimination of either calci-
neurin inhibitors or prednisone should be
taken into account for selected patients with
recognized risk factors for graft loss and/or
death.
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